Corporate Banner
Satellite Banner
Technology Networks Header
Thursday, September 18, 2014
Technology Networks
 
Register | Sign in
Home Page>Posters

  Posters

In Vitro Potency of Chemically Modified siRNAs Against TNF-alpha
Sandra M. Ocampo, Anna Aviño, Santiago Grijalvo, José C. Perales and Ramón Eritja

The execution of succesful RNAi experiments depends upon multiple factors: 1. Design and identification of effective and specific siRNA sites 2. Enhancement of pharmacocinetic properties 3. Delivery of siRNA. Therefore we have designed, prepared and functionality tested a variety of chemical modifications. These have been tested in HeLa cells to ascertain wether they influence RNAi inducing activity. We have chosen tumor necrosis factor (TNF-alpha) as a target.

More information
Critical factors for successful RNAi experiments in primary cells and hard to transfect cell lines
Markus Zumbansen1, Nicole Spottke1, Sheila Offizier1, Allison St. Amand2, Devin Leake2, Ludger Altrogge1, Meike Weigel1, Sandra Domzalski1, Dietmar Lenz, and Herbert Müller-Hartmann1

The amaxa Nucleofector® Technology is a well established method for effective, non-viral transfection of any nucleic acid substrate into hard-to-transfect cells, especially suspension and primary cells. With the Nucleofector® 96-well Shuttle® system high throughput applications such as siRNA-library screenings have become amenable for the first time in these cell types. This renders target validation and identification possible in cell types highly relevant for biomedical research. Here we dis

More information
Highly Efficient High-Throughput Transfection
Markus Zumbansen1, Allison St. Amand2, Devin Leake2, Ludger Altrogge1, and Herbert Müller-Hartmann1

Successful RNAi experiments and large-scale siRNA screens require efficient delivery of highly functional and specific nucleic acids including siRNA oligonucleotides, shRNA vectors, or micro RNAs into an appropriate cell system. Cell types relevant for immunological research, such as primary T cells and several suspension cell lines, are poorly accessible using reagent-based transfection approaches.

More information
Automated High Throughput Nucleofection®
Claudia Merz, Andreas Schroers, Eric Willimann

Using primary cells for RNAi based applications such as target identification or – validation, requires a highly efficient transfection technology in combination with a reliable and robust automation system. To accomplish these requirements we integrated the amaxa 96-well Shuttle® in a Tecan Freedom EVO® cell transfection workstation which is based on Tecan’s Freedom EVO® liquid handling platform and include all the necessary components and features for unattended cell transfection.

More information
DOCKING STUDIES OF A NEW HETEROCYCLIC METHYLTHIOMORPHOLIN PHENOLS DERIVATIVES AS ANTIHYPERTENSIVE DRUGS WITH ACE TARGET.CASE FESCDIPINE II
1V. Vázquez,1O. Vázquez, 1,2M.A.Balboa, 1A. Ma. Velázquez, 1V.H. Abrego, 1B.Camacho, 1L. Martínez, 1L.A. Torres, 1A. Ramírez, 1I.Martínez, 3R.López-Castañares, 1S.Díaz-Barriga, 4J. Bocanegra, 4Froylan Gómez-Laguna, 1F. Olvera, 1E.Angeles.

As part of the Drug Design in Medicinal Chemistry Program of the UNAM, new methylthiomorpholinphenol compounds with cardiovascular effect, were studied. One of them, FESCDIPINE II, was an excellent antihypertensive drug, that has low toxicity and preliminary studies indicate that the Angiotensin-converting enzyme (ACE) system is the biological target of this compound.

More information
Use of gamma scinitigraphy to understand inhaled device/formulation variables on delivery efficiency and
Peter Scholes and Karen Jones

Systemic delivery of both small molecules and macromolecules via inhaled therapies is an area of significant ongoing research1. The pulmonary route offers the physiological benefits of a highly vascularised, large surface area for absorption which can promote high bioavailability and a rapid onset of action. For biomolecules such as peptides, proteins and nucleic acid derivatives, inhaled drug delivery can also provide a viable alterative to intravenous administration.

More information
Quantifying the Impact of a Drug on Gastric Emptying: Measuring the Pharmacodynamic Effect in Clinical Trials
A Rankin, M Paterson, A Connor

Many drug classes are known to alter the rate of gastric emptying. Whilst there is no specific regulatory guidance requiring the impact of drugs on GE to be measured, it is important to fully understand the mode of action and the relationship between the pharmacokinetic profile and the pharmacodynamic response.

More information
Building Flexibility ino Phase I Protocols and Early Clinical Development Programs
Lloyd Stevens and Gareth King

The transition of a drug candidate into Phase I and other early drug development programs is undergoing considerable examination and change. This has largely been brought about by commercial and scientific drivers to reduce attrition rates coupled with an evolving regulatory environment, all of which encourage the pharmaceutical industry to build both scientific focus and flexibility into the drug development program.

More information
Evaluation of Human Regional Bioavailability to Assess Whether Modified Release Development is Feasible
A Connor, G King and K Jones

Many modified release (MR) oral formulations rely on bioavailability from the distal regions of the gastrointestinal (GI) tract (i.e. the ileum and colon). Therefore, by assessing the bioavailability of a drug following delivery to the distal intestines, it is possible to determine whether MR formulation development is achievable.

More information
<< 6 7 8 9 10 11 12 >>
Showing Results 81 - 90 of 145
Scientific News
Genetic Testing for Prostate Cancer
Genetic testing can identify men at six-fold increased risk of prostate cancer.
Redefining High Risk Patients With Stage II Colon Cancer
microRNA-21 identified as an independent prognostic biomarker.
Leukemia Subtype Becomes More Common With Age
Genomic Analysis of 1,725 patients reveals the prevalence of Ph-like ALL increases with age.
Ovarian Cancer Oncogene Found in "Junk DNA"
The study is published online in this week in Cancer Cell.
New Genetic Target for a Different Kind of Cancer Drug
Upstream of the proteins that cancer cells use to proliferate sits RBM4, a gene-splicing protein that is drastically reduced in human lung and breast cancer cells.
Combination microRNA Therapy Suppresses Non-Small-Cell Lung Cancer
Findings offer a promising therapeutic avenue for NSCLC.
Breakthrough Melanoma Treatment, Keytruda, Developed
New immunotherapy launched in the US for treatment of adults with advanced melanoma, developed using antibody humanization expertise at UK’s MRC Technology.
New Gene Mutations for Wilms Tumor
UT Southwestern researchers identified the mutated genes by sequencing the DNA of 44 tumors.
New Sequence of Naked Mole Rat Genome Facilitates Cancer Resistance Research
Director of Science at The Genome Analysis Centre (TGAC) Federica Di Palma co-authors new genetic study on the naked mole rat’s resistance to cancer, identifying key genomic variations that may have contributed to the evolution of this extraordinary species.
Repressing the Repressors May Drive Tissue-Specific Cancers
Stowers scientists establish Drosophila and mammalian models to study mutations found in pediatric brain tumors.
Skyscraper Banner
Skyscraper Banner
Follow TechNetcom1 on Twitter
Technology Networks Ltd. on LinkedIn
Go to LabTube.tv